Axsome Logo.png
Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021 07:00 ET | Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...
AMR Logo.png
Global Narcolepsy Drugs Market Size to Hit $6.66 Billion by 2030: Allied Market Research
October 05, 2021 10:11 ET | Allied Market Research
Portland, OR, Oct. 05, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Narcolepsy Drugs Market was worth $2.68 billion in 2020, and is projected to...
Axsome Logo.png
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
September 16, 2021 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
TIP_link_300x300.jpg
Narcolepsy Market Growth Sturdy at 9.5% CAGR to Outstrip $4,537.9 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com
May 18, 2021 19:25 ET | The Insight Partners
Pune, India., May 19, 2021 (GLOBE NEWSWIRE) -- Narcolepsy Market: Key InsightsAccording to our new research study on “Narcolepsy Market to 2027 – Global Analysis and Forecast – by Type, Product, and...
Graphical Research.jpg
Sleep Tech Devices Market Trends 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
May 10, 2021 06:00 ET | Graphical Research
Pune, India, May 10, 2021 (GLOBE NEWSWIRE) -- The global sleep tech devices market size is predicted to show tremendous growth during the forecast period owing to the growing need among...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 21, 2020 07:00 ET | Axsome Therapeutics, Inc.
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...
axsomelogo-468x57.jpg
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 28, 2020 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
axsomelogo-468x57.jpg
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
August 05, 2020 07:00 ET | Axsome Therapeutics, Inc.
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
axsomelogo-468x57.jpg
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET | Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET | Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...